Overview

Beta Glucan Assay in Patients Receiving Voriconazole Prophylaxis

Status:
Completed
Trial end date:
2010-07-01
Target enrollment:
Participant gender:
Summary
Objectives: To investigate the relationship between the administration of intravenous (IV) and oral voriconazole (vori) and the occurrence of false positive (1,3) beta-d- glucan (BG) relative to the standard assessment criteria used to diagnose invasive fungal infection in patients with hematologic malignancies.
Phase:
Phase 3
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborator:
Pfizer
Treatments:
Voriconazole